DOCKET NO.:ISIS-4943

In the Specification:

At page 1, please delete the first paragraph of the specification (starting at line 3 and ending at line 20) and add the following replacement paragraph:

This application is a continuation of application Serial No. 09/135,202, filed August 17, 1998, which is a division of application Serial No. 08/471,973, filed on June 6, 1995 (now U.S. Patent No. 5,872,232) and a continuation-in-part of application Serial No. 08/465,880, filed on June 6, 1995 (now U.S. Patent No. 5,955,589). Application Serial No. 08/465,880 is a continuation-in-part of application Serial No. 08/244,993, filed on June 21, 1994 (now U.S. Patent No. 5,623,065), which is the U.S. national phase application of International application PCT/US92/11339, filed on December 23, 1992 (now abandoned), and is a continuation-in-part of application Serial No. 07/814,961, filed on December 24, 1991 (now abandoned). Application Serial No. 08/471,973, filed June 6, 1995, is a continuation-in-part of Application serial no. 07/835,932, filed March 5, 1992, which is a U.S. national phase application of International application Serial No. PCT/US91/05720, filed August 12, 1991, which is a PCT continuation-in-part of Application Serial No. 07/566,977, filed August 13, 1990 (now abandoned).

In the Claims

Please add claim 13 and insert claims 8 to 12 as presented below in amended form:

5 N P

8 (Amended). A mixed sequence oligonucleotide or oligonucleotide analog including more than one 2'-modified 2'-deoxyfuranosyl moiety wherein said modification comprises substitution by halo, azido, amino, alkloxy, thioalkoxy, alkylamino, alkyl, and wherein one of

DOCKET NO.: ISIS-4943

PATENT

said 2'-modified 2'-deoxyfuranosyl moieties is different from another of said 2'-modified 2'-deoxyfuranosyl moieties.

9 (Amended). The mixed sequence oligonucleotide or oligonucloetide analog of claim 8, wherein one of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by halo, azido, amino, thioalkoxy, alkylamino or alkyl and another of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by alkyloxy.

10 (Amended). The mixed sequence oligonucleotide or oligonucleotide analog of claim 8, wherein one of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by halo, azido, amino, thioalkoxy or alkyl and another of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by methoxy.

11 (Amended). The mixed sequence oligonucleotide or oligonucleotide analog of claim 8, wherein alkyl comprises a straight or branched chain alkyl.

12 (Amended). The mixed sequence oligonucleotide or oligonucleotide analog of claim 11, wherein alkyl includes unsaturation within the alkyl carbon chain.

13 (New) The mixed sequence oligonucleotide of claim 8 wherein said oligonucleotide is a nuclease resistant oligonucleotide.

3

Sulp.